Tesaro Patient Support: TOGETHER with TESARO

Patient Support Services Guide 2018


Together with Tesaro
844-283-7276

TOGETHER with TESARO is Tesaro’s patient resource program that offers a suite of patient support services focused on assisting patients with access and affordability issues relating to Varubi (rolapitant), an antagonist of the neurokinin 1 receptor, and to Zejula (niraparib), a poly ADP-ribose polymerase (PARP) inhibitor.

Varubi is indicated for the prevention, in combination with other antiemetic drugs, of delayed nausea and vomiting associated with initial and repeated courses of emetogenic, including highly emetogenic, chemotherapy in adults; Zejula is indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy (Table).

TOGETHER with TESARO Services

Together with Tesaro offers a full suite of services for patients who have been prescribed Varubi or Zejula.

The Commercial Co-pay Assistance Program provides financial assistance for eligible, commercially insured patients with out-of-pocket costs for Varubi or Zejula.

The Patient Assistance Program may provide free treatment for uninsured or underinsured patients who meet certain financial eligibility criteria.

The Varubi First Dose Program provides Varubi at no cost in the event of an insurance coverage delay, allowing the patient to start the treatment plan quickly and efficiently.

The Zejula Quick Start and Bridge Programs provide Zejula at no cost to eligible patients who are experiencing insurance coverage delays or interruptions.

TOGETHER with TESARO also provides referrals to patient advocacy organizations and independent copay foundations, for additional financial support, peer-to-peer support, and noncopay support.

Other support services include benefits investigation, verification of insurance approval or coverage, and guidance on insurance processes.

Eligibility

Commercial Co-pay Assistance Program

This program reduces copay or coinsurance for commercially insured patients who are prescribed Varubi to $0, with a $300 cap per Varubi dose and no annual maximum. The patient will be issued a virtual card, which can be initiated and used by pharmacies, at the healthcare provider’s office, in hospital outpatient clinics, and by Biologics.

Qualifying patients with commercial insurance who are prescribed Zejula may pay copays or coinsurance of as little as $0, with an annual benefit limit of up to $26,000. This program has no income requirements. The patient will be issued a virtual card, which can be initiated and used by specialty pharmacies in Tesaro’s limited distribution network or at in-office dispensing sites.

Zejula Quick Start and Bridge Programs

Patients may qualify for a 15-day supply of Zejula at no cost in the event of an insurance coverage delay at first dispense (Quick Start Program), or a coverage interruption for patients already receiving treatment (Bridge Program). Under these programs, up to 5 refills are available, pending resolution of the related coverage delay. Eligibility requirements include:

  • Having a diagnosis consistent with the Zejula package insert
  • Being prescribed Zejula by their physician
  • Having insurance
  • Experiencing an insurance coverage delay of ≥5 business days.

Patient Assistance Program

Patients who are uninsured or underinsured and who meet the financial eligibility criteria may qualify to receive Varubi or Zejula for free through Tesaro’s Patient Assistance Program.

Application & Enrollment

Enrollment requires submission of the enrollment form by the healthcare provider. Patient enrollment can be done in 3 ways:

  • Online at TOGETHERwithTESARO.com
  • By downloading the enrollment form and faxing it to 800-645-9043
  • By contacting a case manager, who can enroll the patient over the phone. Case managers can be found by using your zip code on this website.

Completing the enrollment initiates a benefits investigation to understand the patient’s health insurance, and to select the right support services program. Enrollment requires a healthcare professional’s signature, either that of a prescriber or a legal representative from the provider’s office, attesting to the review of the policy and consent, and providing the prescription for Varubi or Zejula.

Enrollment forms for Varubi and Zejula are available online: Varubi | Zejula.

Other Services

Together with Tesaro also provides the following assistance for patients:

  • Benefits investigation, where a case manager will look into the patient’s specific coverage and benefits details
  • Prior authorization facilitation and appeals support, which offers prior authorization facilitation and appeals support for denied claims
  • Referrals to patient advocacy organizations, education resources, and independent copay foundations, which may offer other means of financial support based on eligibility for these programs and services, in addition to peer-to-peer support and noncopay support (Varubi or Zejula).

Table Tesaro Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Varubi (rolapitant)
Indication
Prevention, in combination with other antiemetic drugs, of delayed nausea and vomiting associated with initial/repeated courses of emetogenic/highly emetogenic chemotherapy in adults

Drug
Zejula (niraparib)
Indication
Maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete/partial response to platinum-based chemotherapy